|
Name |
Oxirane-2-carboxylic acid, 3-(3,4,5-trimethoxyphenyl)-, methyl ester
|
| Molecular Formula | C13H16O6 | |
| IUPAC Name* |
methyl 3-(3,4,5-trimethoxyphenyl)oxirane-2-carboxylate
|
|
| SMILES |
COC1=CC(=CC(=C1OC)OC)C2C(O2)C(=O)OC
|
|
| InChI |
InChI=1S/C13H16O6/c1-15-8-5-7(6-9(16-2)11(8)17-3)10-12(19-10)13(14)18-4/h5-6,10,12H,1-4H3
|
|
| InChIKey |
UAIRDODKPSQSRT-UHFFFAOYSA-N
|
|
| Synonyms |
Oxirane-2-carboxylic acid,3-[3,4,5-trimethoxyphenyl]-, methyl ester; 3-(3,4,5-Trimethoxyphenyl)glycidic acid methyl ester; Methyl 3-(3,4,5-trimethoxyphenyl)-2-oxiranecarboxylate; Methyl 3-(3,4,5-trimethoxyphenyl)-2-oxiranecarboxylate #; Oxirane-2-carboxylic acid, 3-(3,4,5-trimethoxyphenyl)-, methyl ester
|
|
| CAS | NA | |
| PubChem CID | 602508 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 268.26 | ALogp: | 1.3 |
| HBD: | 0 | HBA: | 6 |
| Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 66.5 | Aromatic Rings: | 2 |
| Heavy Atoms: | 19 | QED Weighted: | 0.599 |
| Caco-2 Permeability: | -4.682 | MDCK Permeability: | 0.00004370 |
| Pgp-inhibitor: | 0.593 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.006 |
| 30% Bioavailability (F30%): | 0.229 |
| Blood-Brain-Barrier Penetration (BBB): | 0.988 | Plasma Protein Binding (PPB): | 35.81% |
| Volume Distribution (VD): | 0.615 | Fu: | 34.90% |
| CYP1A2-inhibitor: | 0.063 | CYP1A2-substrate: | 0.954 |
| CYP2C19-inhibitor: | 0.1 | CYP2C19-substrate: | 0.913 |
| CYP2C9-inhibitor: | 0.024 | CYP2C9-substrate: | 0.496 |
| CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.818 |
| CYP3A4-inhibitor: | 0.043 | CYP3A4-substrate: | 0.684 |
| Clearance (CL): | 7.4 | Half-life (T1/2): | 0.659 |
| hERG Blockers: | 0.03 | Human Hepatotoxicity (H-HT): | 0.354 |
| Drug-inuced Liver Injury (DILI): | 0.44 | AMES Toxicity: | 0.208 |
| Rat Oral Acute Toxicity: | 0.154 | Maximum Recommended Daily Dose: | 0.034 |
| Skin Sensitization: | 0.196 | Carcinogencity: | 0.052 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.052 |
| Respiratory Toxicity: | 0.116 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000340 | ![]() |
0.453 | D0AO5H | ![]() |
0.358 | ||
| ENC001396 | ![]() |
0.381 | D0D4HN | ![]() |
0.356 | ||
| ENC005523 | ![]() |
0.381 | D0A8FB | ![]() |
0.354 | ||
| ENC001423 | ![]() |
0.381 | D09DHY | ![]() |
0.347 | ||
| ENC005931 | ![]() |
0.379 | D02LZB | ![]() |
0.337 | ||
| ENC005937 | ![]() |
0.371 | D01FFA | ![]() |
0.313 | ||
| ENC001577 | ![]() |
0.368 | D0Y7TS | ![]() |
0.309 | ||
| ENC001410 | ![]() |
0.368 | D09HDR | ![]() |
0.305 | ||
| ENC005935 | ![]() |
0.367 | D06GCK | ![]() |
0.301 | ||
| ENC005977 | ![]() |
0.363 | D0C1SF | ![]() |
0.300 | ||